Akums Drugs Pharmaceuticals Ltd vs Glaxosmithkline Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Akums Drugs & Pharmaceuticals Ltd is ₹ 552.5 as of 06 May 15:30 . The P/E Ratio of Akums Drugs & Pharmaceuticals Ltd changed from 21.5 on March 2025 to 21.5 on March 2025 . This represents a CAGR of 0.00% over 1 yearsThe P/E Ratio of Glaxosmithkline Pharmaceuticals Ltd changed from 68.1 on March 2021 to 52.5 on March 2025 . This represents a CAGR of -5.07% over 5 years The Market Cap of Akums Drugs & Pharmaceuticals Ltd changed from ₹ 7469 crore on March 2025 to ₹ 7469 crore on March 2025 . This represents a CAGR of 0.00% over 1 yearsThe Market Cap of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 24401 crore on March 2021 to ₹ 48743 crore on March 2025 . This represents a CAGR of 14.84% over 5 years The revenue of Akums Drugs & Pharmaceuticals Ltd for the Dec '25 is ₹ 1193 crore as compare to the Sep '25 revenue of ₹ 1049 crore. This represent the growth of 13.72% The revenue of Glaxosmithkline Pharmaceuticals Ltd for the Dec '25 is ₹ 1091 crore as compare to the Sep '25 revenue of ₹ 1016 crore. This represent the growth of 7.4% The ebitda of Akums Drugs & Pharmaceuticals Ltd for the Dec '25 is ₹ 162.96 crore as compare to the Sep '25 ebitda of ₹ 126.84 crore. This represent the growth of 28.48% The ebitda of Glaxosmithkline Pharmaceuticals Ltd for the Dec '25 is ₹ 421.44 crore as compare to the Sep '25 ebitda of ₹ 371.94 crore. This represent the growth of 13.31% The net profit of Akums Drugs & Pharmaceuticals Ltd changed from ₹ 61.21 crore to ₹ 67.67 crore over 7 quarters. This represents a CAGR of 5.90% The net profit of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 182.33 crore to ₹ 295.62 crore over 7 quarters. This represents a CAGR of 31.80% The Dividend Payout of Akums Drugs & Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Glaxosmithkline Pharmaceuticals Ltd changed from 142.13 % on March 2021 to 99.54 % on March 2025 . This represents a CAGR of -6.88% over 5 years .

About Akums Drugs & Pharmaceuticals Ltd

Akums Drugs and Pharmaceuticals Limited was incorporated vide Certificate of Incorporation dated April 19, 2004 and received a Certificate for Commencement of Business dated May 13, 2004 issued by the RoC. Alkums Drugs & Pharmas are a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas.
They are into sale of branded pharmaceutical formulations and manufacturing of Active Pharmaceutical Ingredients.
Some of the other services include formulation research and development, preparation and filing of regulatory dossiers into the Indian and global markets, and other testing services.
Some of manufacturing units have been accredited by various global regulatory agencies such as the European Good Manufacturing Practice, the World Health Organization Good Manufacturing Practice and the United States National Sanitation Foundation.

About Glaxosmithkline Pharmaceuticals Ltd

GlaxoSmithKline Pharmaceuticals Limited was erstwhile incorporated as 'Glindia Limited' in November, 1924.
The Company' s name was changed to Glaxo (India) Limited' from Glindia Limited in year 1987 and further to 'GlaxoSmithKline Pharmaceuticals Limited' from Glaxo (India) Limited effective from October 22, 2001. GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together.
The Company is headquartered in Mumbai and it has six branch offices, one manufacturing facility at Nashik in Maharashtra, 20 contract manufacturing organisations (CMOs) with regional and sales hubs across India.
The Company is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals.

FAQs for the comparison of Akums Drugs & Pharmaceuticals Ltd and Glaxosmithkline Pharmaceuticals Ltd

Which company has a larger market capitalization, Akums Drugs & Pharmaceuticals Ltd or Glaxosmithkline Pharmaceuticals Ltd?

Market cap of Akums Drugs & Pharmaceuticals Ltd is 8,691 Cr while Market cap of Glaxosmithkline Pharmaceuticals Ltd is 40,017 Cr

What are the key factors driving the stock performance of Akums Drugs & Pharmaceuticals Ltd and Glaxosmithkline Pharmaceuticals Ltd?

The stock performance of Akums Drugs & Pharmaceuticals Ltd and Glaxosmithkline Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Akums Drugs & Pharmaceuticals Ltd and Glaxosmithkline Pharmaceuticals Ltd?

As of May 6, 2026, the Akums Drugs & Pharmaceuticals Ltd stock price is INR ₹552.2. On the other hand, Glaxosmithkline Pharmaceuticals Ltd stock price is INR ₹2362.25.

How do dividend payouts of Akums Drugs & Pharmaceuticals Ltd and Glaxosmithkline Pharmaceuticals Ltd compare?

To compare the dividend payouts of Akums Drugs & Pharmaceuticals Ltd and Glaxosmithkline Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.